SCHEMBL21624879

SCHEMBL21624879

CCOC(=O)Cc1ccc(N2CCN(C)CC2)cc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.55
ALDH1A1 P00352 3/20 0.55
LMNA P02545 3/20 0.51
KDM4E B2RXH2 1/20 0.51
GAA P10253 1/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
CHKA P35790 1/20 0.50
LIPE Q05469 1/20 0.49
HDAC3 O15379 2/20 0.48
HDAC8 Q9BY41 2/20 0.48
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
GFER P55789 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
TP53 P04637 1/20 0.46
CYP4Z1 Q86W10 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17316376 0.88 LIPE (0.51) MAPTALDH1A1LMNAKDM4EGAA
SCHEMBL11872337 0.87 MAPT (0.54) MAPTALDH1A1LMNAKDM4EGAA
SCHEMBL23387298 0.86 ALDH1A1 (0.52) MAPTALDH1A1LMNAKDM4EGAA
SCHEMBL6596281 0.85 LIPE (0.62) MAPTALDH1A1LMNAKDM4EGAA
SCHEMBL2370530 0.85 SMN1; SMN2 (0.60) MAPTALDH1A1LMNAGAANPC1
SCHEMBL24059107 0.84 LIPE (0.50) MAPTALDH1A1LMNAKDM4EGAA
SCHEMBL8349447 0.84 ADRB1 (0.50) MAPTALDH1A1LMNAKDM4EGAA
SCHEMBL11848012 0.84 LIPE (0.48) MAPTALDH1A1LMNAKDM4EGAA
SCHEMBL29098498 0.83 S1PR1 (0.60) MAPTALDH1A1LMNAKDM4EGAA
SCHEMBL17420453 0.83 AGXT (0.56) MAPTALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107474024-B Glutaminase inhibitor and composition and application thereof 北京赛林泰医药技术有限公司 2022-12-13 CN disclosed
US-20220363667-A1 T-TYPE CALCIUM CHANNEL BLOCKER NIPPON CHEMIPHAR CO., LTD. (JP) 2022-11-17 US disclosed
US-20220226299-A1 USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS NIPPON CHEMIPHAR CO., LTD. (JP) 2022-07-21 US disclosed
EP-3950059-A1 USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS Nippon Chemiphar Co., Ltd. (JP) 2022-02-09 EP disclosed
EP-3825303-A1 T-TYPE CALCIUM CHANNEL BLOCKER Nippon Chemiphar Co., Ltd. (JP) 2021-05-26 EP disclosed
WO-2020203609-A1 USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS 日本ケミファ株式会社 2020-10-08 WO disclosed
WO-2020203610-A1 USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING RHEUMATOID ARTHRITIS 日本ケミファ株式会社 2020-10-08 WO disclosed
WO-2020017569-A1 T-TYPE CALCIUM CHANNEL BLOCKER 日本ケミファ株式会社 2020-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220363667-A1 T-TYPE CALCIUM CHANNEL BLOCKER CACNA1I, CACNA1G, CACNA1H MAPT 304/4885ALDH1A1 3434/4885LMNA 3066/4885
US-20220226299-A1 USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS TRPV3, CACNA1G, TRPV2 MAPT 143/4885ALDH1A1 3671/4885LMNA 3286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.